United Kingdom Research and Innovation

King's College London

Imperial Innovations Limited

Vyzkumny Ustav Veterinarniho Lekarstvi, V.v.i.

Imuthes Limited

Ic-vec Limited

Pronovo Biopharma Norge As

Institute of Organic Chemistry and Biochemistry Av Cr, V.v.i.

Medical Research Council

Thia Medica As

Andrew David Miller

Jimmy David Bell

Rolf Kristian Berge

Jaroslav Turanek

Miroslav Ledvina

Gary Frost

Tammy Louise Kalber

Wladyslaw Gedroyc

Michael James Lee Wright

Miguel Centelles

Maria Thanou

Christopher J Etheridge

Robert G Cooper

Jon Skorve

Michael R Jørgensen

Rolf Berge

Karsten Hipler

Meliz Sahuri Arisoylu

Leigh Brody

Elizabeth Louise Thomas

Maya Thanou

Gavin David Kenny

Nazila Kamaly

Michael Rael Jorgensen

Jimmy Bell

The invention provides a (drug-containing) lipid nanoparticle with: The lipid nanoparticle can release a drug (or API) from within the lipid nanoparticle as a result of focused ultrasound (FUS) applied continuously, at least twice, to a desired part of the body to induce hyperthermia (an increase in temperature). FUS is applied after the lipid nanoparticle containing the drug has been administered to the live subject, and causes controlled release of the drug at the desired site of the body. Ultrasound is then halted, and the site of interest allowed to cool. Ultrasound is then applied again. Lipid nanoparticles can be labelled (for MRI, NIRF imaging), enabling real time monitoring of the drug in the human body. Imaging information can be used to direct and guide the nature of the FUS applied to the site of interest.

Nanoparticles

The present invention provides novel liposomes comprising Gd.DOTA.DSA (gadolinium (III) 2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N'-amido-methyl]-1,4,7,10- =tetra-azacyclododec-1-yl}-acetic acid), characterised in that the liposome further comprises a neutral, fully saturated phospholipid component (e.g. DSPC (1,2-distearoyl-sn-glycero-3-phospocholine]), which are of particular use in the preparation of magnetic resonance contrast agents for enhancing a magnetic resonance image of tumours in a mammal.

Liposome nanoparticles for tumor magnetic resonance imaging

The present invention concerns nanoparticle formulations suitable for the delivery of one or more therapeutic agents, the formulations comprising: a cationic cholesterol derivative; a neutral phospholipid; cholesterol or a neutral cholesterol derivative; and a saturated fatty acid, PEGylated neutral derivative of phosphatidylethanolamine or phosphatidylcholine.

Nanoparticle formulation

The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein RRRRand Rare each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; Ris a hydroxyl, a hydrocarbyl, a lipid moiety, a lipid acyl moiety; or an amino hydrocarbyl group optionally substituted with a hydrocarbyl, a lipid moiety or a lipid acyl moiety; Rand Rare each independently selected from acetyl, a hydrocarbyl, a lipid moiety and a lipid acyl moiety; X is a peptide chain; The above normuramylglycopeptide compounds can be located in liposomes and micelles and can function as immunomodulators, along with a desired antigen (or DNA encloding the antigen), in (e.g. DNA) vaccines.

Normuramyl glycopeptide compounds

The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X&#x2014;Y&#x2014;Z&#x2014;, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula &#x2014;[C(O)]PHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.

Sulfur-containing phospholipid derivatives

A compound capable of acting as a cationic lipid is described. The compound comprises a cholesterol group having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol.

Polycationic sterol derivatives as transfection agents

Growing community of inventors

London, United Kingdom

Andrew David Miller